OptiVitro® NK Cel Expansion Serum-free Kit Series are designed for the in vitro expansion of human natural killer iNK) cell sit is serum-free, xeno-free, and support high vields of functional human NK cells from peripheral blood mononuclear cells(PBMCs) and cord blood mononuclear cells(CB-MNCs).
1、Serum-free,xeno-free, animal-original-free Medium
2、Selection of full factor kit, amplification kit and basic medium as required
3、Support NK cell steady proliferation, high viability, high expansion, high purity, high killing function
4、Suitable for different NK cell culture systems with or without the use of feeder cells
5、Support a variety of NK cell sources (peripheral blood, cord blood, NK-92 cell line, ipsc, etc.) culture
6、Completely independent research and development, stable supply, GMp level, DMf filed (file No.038570), support clinical application and commercialization(Multiple IND application cases approved)
Serum-free, xeno-free;
Robust NK cell expansion;
Work with feeder or feeder-free culture system;
GMP grade, facilitate regulatory approval.
Serum-free, xeno-free
All-in-one, full-cytokines Kit
Robust NK cell expansion
GMP grade, facilitate regulatory approval
Serum-free, xeno-free
As a replenishment of a full-cytokines kit
Robust NK cell expansion
Work with feeder or feeder-free culture system
GMP grade, facilitate regulatory approval.
| Product number | Name | Specifications | components |
|---|---|---|---|
| NE000-N022 | OptiVitro NK cells expansion kit P01 | 1 Kit | Basicmedium（1 L）+Added components+ cytokineⅠ+cytokineⅡ+cytokineⅢ |
| NE000-N032 | OptiVitro NK cells expansion Basic kit P01 | 1 Kit | Basicmedium（1 L）+Added components+cytokineⅢ |
| NE000-N012 | OptiVitro NK cells expansion Serum-free Medium P01 | 1 Kit | Basicmedium（1 L）+Added components |
| NE000-N042 | OptiVitro NK cells expansion Serum-free Medium NE01（phenol red-free） | 1 Kit | Basicmedium（1 L）+Added components |
| NE000-N052 | OptiVitro NK cells expansion kit NE01（phenol red-free） | 1 Kit | Basicmedium（1 L）+Added components+cytokineⅠ+cytokineⅡ+cytokineⅢ |
| NE000-N062 | OptiVitro NK cells expansion Basic kit NE01（phenol red-free） | 1 Kit | Basicmedium（1 L）+Added components+cytokineⅢ |
1000L Fully-automatic Liquid Filling line
Stainless steel liquid blending system
Equipped with 200L & 1000L fully-automatic liquid filling line
B+A grade filling workshop
Stainless steel liquid dosing system to support CIP & SIP
GMP certified facility
CGT serum-free medium has facilitated the successful approval of IND applications for multiple clients in both China and the United States by FDA and CDE, covering multiple technical pipelines such as TCR-T, TIL, γδ-T, CAR-T, UCAR-T, and general-purpose NK cells.
| Pepline | Type | Indications | Authorization | Date | Status |
|---|---|---|---|---|---|
| BRL03 | TCR-T | Advanced solid tumors (lung cancer, advanced stage, etc.) | FDA | 2023.9.9 | Approved |
| BRL03 | TCR-T | Advanced solid tumors (lung cancer, advanced stage, etc.) | CDE | 2023.10.25 | Accepting |
| 2024.1.15 | Approved | ||||
| BST02 | TIL | Liver cancer | FDA | 2023.10.26 | Approved |
| BST02 | TIL | Liver cancer | CDE | 2023.11.3 | Accepting |
| NK510 | Base Editing Directed NK | Advanced solid tumors | CDE | 2024.07.29 | Approved |
| γδ T Cell(GD Kongming) | γδ-T | Hepatocellular Carcinoma | CDE | 2024.01.31 | Approved |
| NK510 | Base Editing Directed NK | Advanced solid tumors | FDA | 2024.11.30 | Approved |
| UC101 | UCAR-T | CD19 | FDA | 2025.01.24 | Approved |
| UTAA09 | UCAR-Vδ1T | B-ALL | CDE | 2025.01.23 | Approved |
| BRG01 | CAR-T | EVB | FDA | 2025.01.31 | Change Approved |
| SA102 | CAR-T | BCMA | CDE | 2025.06.18 |
Plasma+ culture system, medium suoplemented with heat-inactivated autologous plasma, obtain a density at 4.62E6 cells/mL, equal to 5.86E9 cells in total on Day 14, the culture volume is about 1.3L. Plasma- culture system, obtain a density at 3.86E6 cells/ml, equal to 3.00E9 cells in total on Day 14, the culture volume is about 0.8L.
Materials:T25 Flasks,T75 Flasks, 2L Bags
B-MNCs: Seeding density at 2.5E6 cells/mL, equal to 1.25E7cells in total.
Figure 9. Cytolytic function test. Human NK cells from PBMCs, can kill target K562 cells in a dose-dependent manner.
Visit our FAQ database to get answers to various questions about using the product.
Contact our technical expert team for professional product support and application guidance.